"I don't know how I'm supposed to have longevity in this career," said one researcher.December 9, 2025Check out STAT+Sponsored By Laura Weiler for STAT Early-career trans researchers reconsider their futures amid lost funding and fear Trans researchers saw their funding, their work, their humanity targeted by the Trump administration: Part 6 of 'American Science, Shattered' By Theresa Gaffney STAT+ | Opinion: FDA drug center's new acting director fits a pattern of risky, internal contradictions among agency leadership The FDA is tightening evidence demands for some products while loosening them for others. Expert says growing contradictions reflect ideology, not science. By Paul Knoepfler STAT+ | J&J's two-drug combo blocked tumors in advanced multiple myeloma ASH's 2025 meeting ended with strong multiple myeloma data from J&J, a new treatment for a rare disorder, and strains on a sickle-cell data program. By Adam Feuerstein, Angus Chen, Damian Garde, and Katherine MacPhail Sarah Silbiger/Getty Images Opinion: It's past time to update the rules intended to slow the FDA's revolving door Current post-employment rules fail to prevent the appearance (and too often the reality) of regulatory capture, especially with the FDA. By Lee Rosebush and Marc Wagner More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Daily Recap? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2025, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments